CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
- Conditions
- Neoplasm MetastasisSarcoma, Ewing
- Interventions
- Registration Number
- NCT05440786
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 45
-
Diagnosis of Ewing's sarcoma or Ewing's sarcoma-like tumor by institutional pathologist. The original pathological report is required. Repeat biopsy at progression is not required
-
Refractory disease or confirmed radiological progression or recurrence following first or later line of treatment of Ewing's sarcoma or Ewing's sarcoma-like tumor
-- Must have one measurable or evaluable lesion per RECIST 1.1
-
Adequate performance status based on age
- For participants less than (<)16 years of age, a Lansky score greater than or equal to (≥)50, or
- For participants ≥16 years of age, a Karnofsky score ≥50
-
Participants must have discontinued all previous treatments for cancer or investigational agents ≥7 days after the last dose and must have recovered from the acute effects
-
Adequate hematologic and organ function less than or equal to (≤)14 days prior to Day 1 of Cycle 1:
- Absolute neutrophil count ≥1000/microliter (µL)
- Platelets ≥75,000/cubic millimeter (mm³)
- Hemoglobin ≥8 grams per deciLiter (g/Dl) (≥100 grams per Liter [g/L])
- Total bilirubin ≤1.5 times (×) upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
- Creatinine clearance or calculated glomerular filtration rate (GFR) ≥60 milliliters per minute per square meter (Ml/min/m²) or serum creatinine based on age/gender
-
Female participants of childbearing potential must have a negative urine or serum pregnancy test
-
Body weight ≥10 kilograms (kg)
-
Must be able to swallow and/or have a gastric/nasogastric tube
-- Participants in the European Union must be able to swallow intact capsules
-
Stable or decreasing dose of steroids at least 7 days prior to enrollment
-
Life expectancy of at least 8 weeks and able to complete at least 1 cycle of treatment
-
Participants/caregivers are able and willing to make themselves available for the duration of the study and are willing to follow study procedures, including adherence to the pharmacokinetic (PK) sampling schedule
-
Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
-
Participants with an active fungal, bacterial, and/or known severe viral infection including, but not limited to, human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis.
-
Participants who have had allogeneic bone marrow or solid organ transplant
-
Surgery: Participants who have had, or are planning to have, the following invasive procedures:
- Major surgical procedure, laparoscopic procedure, or significant traumatic injury within 28 days prior to enrollment
- Surgical or other wounds must be adequately healed prior to enrollment
-
Female participants who are pregnant or breastfeeding
-
Have received any prior cyclin-dependent kinase (CDK) 4 and 6 inhibitor
-
Progression during prior treatment with irinotecan and/or temozolomide
-
Have a known intolerability or hypersensitivity to any of the study treatments or dacarbazine
-
Diagnosed and/or treated additional malignancy within 3 years prior to enrollment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Abemaciclib + Irinotecan +Temozolomide Irinotecan Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally. Abemaciclib + Irinotecan +Temozolomide Abemaciclib Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally. Abemaciclib + Irinotecan +Temozolomide Temozolomide Abemaciclib given orally in combination with irinotecan given IV and temozolomide given orally. Irinotecan +Temozolomide Irinotecan Irinotecan given IV and temozolomide orally. Irinotecan +Temozolomide Temozolomide Irinotecan given IV and temozolomide orally.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) Baseline to objective progression or death due to any cause (estimated up to 11 months) PFS determined by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)
- Secondary Outcome Measures
Name Time Method Duration of Response (DoR) Date of first evidence of CR or PR to date of disease recurrence, objective disease progression, or death due to any cause (estimated up to 11 months) DoR
Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR Baseline to measured progressive disease (estimated up to 11 months) ORR
Overall Survival (OS) Baseline to date of death due to any cause (estimated up to 45 months) OS
Pharmacokinetics (PK): Minimum Plasma Concentration (Cmin) of Abemaciclib Cycle 3, Day 1 (21 day cycles) PK: Cmin of Abemaciclib
Abemaciclib Product Acceptability Day 1 of Cycles 1 through 3 (21 day cycles) Participants evaluated abemaciclib acceptability (palatability and ease of administration) using a 5-category questionnaire. Participants were asked to select one of the following to describe the acceptability of abemaciclib: Very difficult, difficult, neither easy nor difficult, easy, or very easy.
Disease Control Rate (DCR) Baseline to measured progressive disease (estimated up to 11 months) DCR
PFS Baseline to objective progression or death due to any cause (estimated up to 11 months) PFS determined by investigator assessment using RECIST 1.1
Trial Locations
- Locations (27)
Lifespan Cancer Institute
🇺🇸Providence, Rhode Island, United States
The Children's Hospital at Westmead
🇦🇺Westmead, New South Wales, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸València, Spain
Phoenix Children's Hospital
🇺🇸Phoenix, Arizona, United States
The Regents of the University of California - Los Angeles (UCLA Pediatrics)
🇺🇸Los Angeles, California, United States
Riley Hospital for Children at Indiana University Health
🇺🇸Indianapolis, Indiana, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
Royal Children's Hospital
🇦🇺Melbourne, Victoria, Australia
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
🇫🇷Bordeaux, Aquitaine, France
Centre Leon Berard
🇫🇷Lyon, Rhône-Alpes, France
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Baden-Württemberg, Germany
Universitätsklinikum Essen
🇩🇪Essen, Nordrhein-Westfalen, Germany
Charité Campus Virchow-Klinikum
🇩🇪Berlin, Germany
Fondazione Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
IRCCS Istituto Ortopedico Rizzoli
🇮🇹Bologna, Italy
Hyogo Prefectural Kobe Children's Hospital
🇯🇵Kobe, Hyogo, Japan
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Hospital Sant Joan de Déu
🇪🇸Esplugues de Llobregat, Barcelona [Barcelona], Spain
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Catalunya [Cataluña], Spain
Hospital Infantil Universitario Niño Jesús
🇪🇸Madrid, Madrid, Comunidad De, Spain